Home / Resources / On-Demand Webinar / PBPK modeling approaches to assess risks associated with bioequivalence in drug development
PBPK modeling approaches to assess risks associated with bioequivalence in drug development

In this webinar, Dr. Ioannis Loisios-Konstantinidis from Novartis, Switzerland discussed:

  • Opportunities and challenges in conducting virtual bioequivalence
  • IVIVE-PBPK in biopharmaceutics
  • An quantitative risk assessment approach for virtual bioequivalence
  • Role of inter-occasion variability and pharmacokinetic properties in virtual bioequivalence
Back to top